SPYRE THERAPEUTICS INC (SYRE) Stock Income Statement
NASDAQ:SYRE - Nasdaq - US00773J2024 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 886.00K | 2.33M | 18.74M | 0.00 | |||
| Operating Expenses | 208.57M | 118.50M | 87.11M | 84.39M | 81.48M | |||
| Research and Development | 162.79M | 84.05M | 58.58M | 57.07M | 59.64M | |||
| Selling, General, and Administrative Expenses | 45.78M | 34.45M | 28.53M | 27.32M | 21.84M | |||
| Operating Income | -208.57M | -117.61M | -84.78M | -65.65M | -81.48M | |||
| Interest Income/Expense | 21.31M | 25.13M | 840.00K | 110.00K | 590.00K | |||
| Other Income/Expense | -20.71M | -121.65M | -10.00K | -120.00K | -10.00K | |||
| Non Recurring Items | 0.00 | -124.69M | N/A | N/A | N/A | |||
| Income Before Taxes | -207.97M | -338.82M | -83.95M | -65.66M | -80.89M | |||
| Income Tax | 51.00K | -26.00K | -140.00K | 140.00K | N/A | |||
| Net Income | -208.02M | -338.79M | -83.82M | -65.80M | -80.89M | |||
| EBITDA | N/A | -116.87M | -83.21M | -64.07M | -80.48M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.42 | -49.12 | -24.86 | -25.02 | -37.97 | |||
| Non GAAP EPS | -4.23 | -59.89 | -25.25 | -8.44 | -1.61 | |||
| Statistics | ||||||||
| Profit Margin | N/A | -38238.15% | -3597.42% | -351.12% | N/A | |||
| Operating Profit Margin | N/A | -13274.49% | -3638.63% | -350.32% | N/A | |||
All data in USD